Glycosaminoglycan regulatory associated long non-coding RNA (GRASLND)

Glycosaminoglycan regulatory associated long non-coding RNA (GRASLND), also known as RNF144A-AS1, is a primate-specific long non-coding RNA (lncRNA) regulator that plays a critical role in mesenchymal stem cell chondrogenesis and cartilage matrix production, primarily via suppression of the interferon-gamma signaling pathway through EIF2AK2 binding[1]. GRASLND is a key regulator of cartilage differentiation and has therapeutic potential for cartilage regeneration and osteoarthritis treatment[1]. Furthermore, it is overexpressed in various cancers, including melanoma, bladder, gastric, and ovarian cancer, where it promotes tumor proliferation, invasion, metastasis, angiogenesis, and immune evasion—most notably by suppressing IFN-γ-stimulated anti-tumor responses[2][3][4][5][6]. GRASLND is considered an unfavourable prognostic marker in several cancer types, and modulating its expression may offer diagnostic and therapeutic opportunities across oncology and regenerative medicine.

Other names

RNF144A-AS1RNF144A antisense RNA 1 (non-protein coding)GRASLND

Therapeutic manipulation (overexpression, silencing, CRISPR-dCas9 activation) to regulate stem cell chondrogenesis and cartilage regeneration. Suppression of IFN-γ signaling pathway by direct interaction with EIF2AK2. Promotion of tumorigenic signaling pathways such as YAP1. Regulation of EMT via interactions with miRNAs and key proteins (e.g., LOX).